Neumora Therapeutics (NMRA) Equity Ratio (2022 - 2026)

Neumora Therapeutics' Equity Ratio history runs 5 years deep, the most recent figure standing at 0.46 for Q1 2026.

• In Q1 2026, Equity Ratio fell 48.36% year-over-year to 0.46; the TTM figure through Mar 2026 stood at 0.46 (down 48.36% YoY), while the FY2025 annual figure was 0.54, down 39.97% from the prior year.
• Equity Ratio was 0.46 for Q1 2026 at Neumora Therapeutics, down from 0.54 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.95 in Q4 2023 to a low of 1.05 in Q4 2022.
• Historically, Equity Ratio has averaged 0.67 across 5 years, with a median of 0.9 in 2025.
• The sharpest annual moves came in 2023 and 2026: Equity Ratio jumped 190.17% in 2023, then tumbled 48.36% in 2026.
• A 5-year view of Equity Ratio shows it stood at 1.05 in 2022, then surged by 190.17% to 0.95 in 2023, then fell by 4.2% to 0.91 in 2024, then slumped by 39.97% to 0.54 in 2025, then fell by 15.52% to 0.46 in 2026.
• The last three Equity Ratio figures came in at 0.46 (Q1 2026), 0.54 (Q4 2025), and 0.74 (Q3 2025), per Business Quant data.